Fulcrum Therapeutics (FULC) Assets Average (2019 - 2026)

Fulcrum Therapeutics (FULC) has 8 years of Assets Average data on file, last reported at $356.5 million in Q1 2026.

• Assets Average for Q1 2026 came in at $356.5 million, up 41.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $356.5 million (up 41.66% YoY), and the FY2025 annual result was $313.5 million, up 20.95% from the prior year.
• Assets Average rose to $356.5 million in Q1 2026 per FULC's latest filing, from $290.6 million in the prior quarter.
• Over five years, Assets Average peaked at $356.5 million in Q1 2026 and troughed at $207.7 million in Q2 2022.
• A 5-year average of $262.2 million and a median of $263.4 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average surged 59.15% in 2022, then retreated 22.6% in 2025.
• A 5-year view of Assets Average shows it stood at $237.2 million in 2022, then rose by 13.08% to $268.3 million in 2023, then climbed by 0.59% to $269.9 million in 2024, then climbed by 7.67% to $290.6 million in 2025, then grew by 22.7% to $356.5 million in 2026.
• Business Quant data shows FULC's Assets Average at $356.5 million in Q1 2026, $290.6 million in Q4 2025, and $221.8 million in Q3 2025.